Background Investigation Methods, Corporate Intelligence & Due Diligence, e-Discovery Techniques, Investigation & Intelligence Feeds, Judgment Enforcement, Legal Enforcement Cases, Legal Ethics & Intelligence, Legal Technology & Intelligence, Witness Credibility Analysis

FDA rethinks need for comparative efficacy studies for certain biosimilars

Posted by author-avatar
0
Test Logo Transparent

The U.S. Food and Drug Administration (FDA) issued new draft guidance on October 29, 2025, proposing what it said were “major updates to simplify biosimilarity studies and reduce unnecessary clinical testing.”…
By: Hogan Lovells

Newer
Florida Still Stumbling Through Trying To Replace ABA Accreditation
Back to list
Older Examining the Beneficial Use and Regulation of Chemicals: U.S. Senate Committee on Environment & Public Works Chemical Safety, Waste Management, Environmental Justice, and Regulatory Oversight Subcommittee Hearing

Leave a Reply

Your email address will not be published. Required fields are marked *